Known targets — ChEMBL curated mechanism
SLC6A2SLC6A3SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.34 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | GSR | P00390 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL10599628 | 1.00 | CA4 (0.46) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL376348 | 0.97 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL376346 | 0.97 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL29497343 | 0.97 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL30486028 | 0.97 | CA4 (0.48) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL10597781 | 0.95 | CA4 (0.46) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL9241005 | 0.95 | CA4 (0.46) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL17350095 | 0.95 | CA4 (0.46) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL1938078 | 0.95 | CA4 (0.46) | CA4CTSLCPT2CPT1ACA2 | |
| Aspartic Acid SCHEMBL10599244 | 0.95 | CA4 (0.46) | CA4CTSLCPT2CPT1ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0108937-B1 | PROCESS FOR THE PRODUCTION OF AMINO-DICARBOXYLIC ACID-BIVALENT METAL-HALOGEN COMPLEXES AND NOVEL SUCH COMPLEXES | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) | 1989-01-25 | — | — | EP | claimed |
| EP-0108937-A2 | Process for the production of amino-dicarboxylic acid-bivalent metal-halogen complexes and novel such complexes | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) | 1984-05-23 | — | — | EP | claimed |
| US-7523563-B2 | Process for preparing certain hydrohalide metal complex compounds having a specific coarse structure | VERLA-PHARM ARZNEIMITTELFABRIK APOTHEKER H.J.V. EHRLICH GMBH & CO. KG (DE) | 2009-04-28 | — | — | US | disclosed |
| US-20070043229-A1 | Process for preparing certain hydrohalide metal complex compounds having a specific coarse structure | VERLA-PHARM ARZNEIMITTELFABRIK APOTHEKER J.J.V. EHRLICH GMBH & CO. KG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-0108937-B1 | PROCESS FOR THE PRODUCTION OF AMINO-DICARBOXYLIC ACID-BIVALENT METAL-HALOGEN COMPLEXES AND NOVEL SUCH COMPLEXES | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) | 1989-01-25 | — | — | EP | disclosed |
| US-4546195-A | Process for the production of amino-dicarboxylic acid-bivalent metal-halogen complexes and such complexes | VERLA-PHARM, ARZNEIMITTELFABRIK, APOTHEKER H.J.V. EHRLICH GMBH & CO. KG (DE) | 1985-10-08 | — | — | US | disclosed |
| EP-0108937-A2 | Process for the production of amino-dicarboxylic acid-bivalent metal-halogen complexes and novel such complexes | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043229-A1 | Process for preparing certain hydrohalide metal complex compounds having a specific coarse structure | SLC7A5, HRH4, SLC7A1 | CA4 626/4885CTSL 2192/4885CPT2 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.